Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer
Completed
INSYS Therapeutics Inc
Phase 1
2001-08-01
Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL
(Novantrone) and a combination of lyophilized lipids. Mitoxantrone, the active agent in the
investigational formulation, is a currently marketed chemotherapeutic agent. The rationale
for development of liposomal formulations is primarily that of improving the safety profile
of the drug, which may permit dose intensification and/or an increase in the cumulative dose
that may be administered, resulting in enhanced efficacy.
LEM will be given to patients with advanced solid tumors to determine the dose of drug these
patients can tolerate. Patients will receive intravenous LEM every 21 days until the disease
progresses or toxicity occurs requiring treatment discontinuation. Anti-tumor effects of LEM
will be assessed and patients will be evaluated for safety and tolerability.
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
Completed
Massachusetts General Hospital
Phase 2/Phase 3
2004-04-01
Metabolic syndrome is associated with increased inflammatory cytokines and reduced
adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned
that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin,
improving the inflammatory milieu associated with metabolic syndrome.
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
Completed
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2/Phase 3
2004-04-01
Metabolic syndrome is associated with increased inflammatory cytokines and reduced
adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned
that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin,
improving the inflammatory milieu associated with metabolic syndrome.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.